FDA keeps Solid Bio's troubled Duchenne MD gene therapy on clinical lockdown in latest setback

FDA keeps Solid Bio's troubled Duchenne MD gene therapy on clinical lockdown in latest setback

Source: 
Endpoints
snippet: 

Much-maligned Solid Biosciences received yet another spate of bad news late Friday regarding its Duchenne muscular dystrophy gene therapy program.

It’s been almost nine months since the FDA announced a second clinical hold on Solid Bio’s Phase I/II trial for an AAV-based Duchenne MD treatment. And after extending that hold in May, US regulators again decided they needed more info with another extension on Friday.